PrimeTrader (@MadisonReend) header
PrimeTrader (@MadisonReend) profile picture

📊 Long-Term Stock Analyst | Focused on U.S. equities, market trends, and growth opportunities. Research-driven, patient, and disciplined investing.

Long Island City, Queens, New
Joined June 2020
$TE getting investigated
1
4
623
$SLS CDTX buyout story from data to BO. That's our path. 5-10x from here with SLS 009 data.
4
322
$NIO CONGRATULATIONS guys 🍷 NiO opened 4 new swap station 🔥🔥🔥having total of 4274 swap stations in China 🇨🇳 🍷🍷 they also having total of 5603 charging stations in China 🔥🔥🔥with 32,761 chargers🍷🍷NiO power in china have total of 9,877 stations 🇨🇳🇨🇳🇨🇳 They also have 61 swap stations in Europe 🇪🇺 64 chargers in Europe 🇪🇺 1 swap station in UAE 🇦🇪 Power up baby ‼️‼️‼️‼️‼️‼️‼️ Let’s go 1,000,000,000 milestone 🫡 Soon will swap the world 🌍🔥🔥
1
4
20
921
$VKTX The Road to a Potential 2029 Launch 2027 is expected to bring the first major Phase 3 results for VK2735, plus maintenance data and progress with VK3019. Oral VK2735 Phase 3 results are expected in 2028. Viking targets a potential 2029 launch, subject to approval. 2027 – Decision Year • First major Phase 3 results for VK2735 (H2 2027). • Second maintenance study results (mid-2027). • Further progress with VK3019, Viking's amylin candidate. 2028 – Validation Year • Results from the oral VK2735 Phase 3 trials. • VANQUISH extension study results. • Further data on safety, effectiveness and long-term weight maintenance. 2029 – Commercialization • Potential regulatory submissions and approval. • Targeted market launch of VK2735. • Start of sales and potential revenue. Looking Ahead – My Take The 2027–2029 period could be a turning point for Viking. Positive clinical results and regulatory approval could make the company a major player in the fast-growing obesity-treatment market.
6
550
$NWBO Did I miss this discussion from the 10Q? "Part I, Item 1 — Financial Statements, page 21, Note 13: Commitments and Contingencies, under the heading Operating Lease – Lessee Arrangements. Exact disclosure: "On August 5, 2026, the Company entered into an 18-month agreement for dedicated laboratory and office space for Flaskworks in Somerville, Massachusetts (the “Lease”). The Lease commenced on August 10, 2026 and provides for monthly payments of $23,900, subject to a 5% increase after the first year. " Chat GPT: An 18-month lease in Somerville, MA, for $23,900 per month is not an insignificant commitment. That represents roughly $437,000 in rent over the 18-month term, before any other costs. Somerville, MA is an interesting location for Flaskworks because it's part of the Greater Boston biotech and life-sciences corridor—one of the largest concentrations of biotech companies, research laboratories, cell-therapy companies, universities, and specialized engineering talent in the US.
1
6
857
$IOVA I like it Pipeline stacked 2027 is going to be lit
4
239
$IONQ 🕵️‍♂️💪🚀This one is more meaningful than a generic partnership announcement-I would rank this development higher than the Northrop Grumman MOU in terms of immediate technical and commercial relevance to IonQ's quantum networking and cybersecurity business. Why? Because this announcement describes a specific interoperability validation between two technologies: - IonQ's Quantum Key Distribution (QKD) systems. - IDEMIA Secure Transactions' cybersecurity platform, IDEMIA Sphere. The companies say they demonstrated that quantum-generated keys can be integrated into enterprise security environments while maintaining existing security controls, compliance requirements and operational workflows. VARINDIA+1 That is a tangible technical milestone.
1
5
20
2,043
$PLUG ANOTHER HEADS UP Plug expects Material-Handling business in Q4 may exceed the previous nine months combined. Management’s statement includes: 1. Walmart refresh units 2. New GenDrive deployments 3. Amazon and other customer refreshes Excluding a $40M dispute settlement, Plug's revenue for the first nine months was $516 million. Historically, material handling has made up roughly 25%–35% of Plug's revenue. 1. 25% x $516 million = $129 million 2. 30% x $516 million = $155 million 3. 35% x $516 million = $180 million Material handling will be a major driver of Q4 growth. The Walmart refresh cycle of 2,000-2,500 units adds roughly $40-$50 million in Q4 material-handling revenue. To top the prior nine months, Q4 material-handling revenue range is between $130-$180 million. My best estimate is that management was pointing to roughly $150 to $160 million of Q4 material-handling revenue. That also fits with $280 million Q4 revenue and positive EBITDA through operating leverage
2
6
1
39
2,004
A dedicated WhatsApp group for $PLUG holders is now online! All investors holding $PLUG stock are welcome to join this exclusive group to discuss the stock and get the latest information. Click the link to send“stock” join: stockswhatsapp.app/9UOw3k Our assistant Jennifer is available to assist you anytime!
15
A dedicated WhatsApp group for $NIO holders is now online! All investors holding $NIO stock are welcome to join this exclusive group to discuss the stock and get the latest information. Click the link to send“stock” join: stockswhatsapp.app/9UOw3k Our assistant Jennifer is available to assist you anytime!
$NIO not a fan of having same day earnings and November delivry numbers…let’s see 👍🏼👍🏼
2
324
$ALT Evercore is one of the most prestigious independent investment banks in healthcare M&A, particularly when it comes to negotiating complex transactions between biotech companies and large pharmaceutical companies.
1
134
$BABA EPS missed $1.21 vs $1.65, cloud +53% no save. Broke 84.22 low, dead til reclaim. $WMT beat $0.65 vs $0.64, guide raised, still red ~126. Lose 125.07 Wed low and it slides. $TTWO GTA VI live today, 99 Metacritic, selling the news, testing 210.50 Wed low premarket. $CAPR FDA calls Deramiocel Sunday Nov 22. Binary at ~$8, panel already voted it down once. $PANW monster beat $3.44B vs $3.31B, guide raised. ~370 premarket, hold 342 and it runs.
1
136
$AMFN ANT gonna suck all the air out of the room the rest of the week, I’d call this week a wash, switch focus to next week. ANT being successful is a bellwether for the general AI trade anyways, so that’ll be good for us big picture if it does well. next week is supposed to be the interesting week anyhow. also, low key, want you all to consider how many adversary countries, conventional energy fields and companies would be threatened by a technology like this succeeding, and ask yourself if it would be worth the expense for said countries or companies to invest in some FUDbots to attack the company while it’s still young and easy to attempt to control sentiment around. remember, bobo never gets to bust.
1
9
448
$IOVA The reduced dose for lymphodepletion was implemented in 2024. Jefferies Global Healthcare Conference Nov 16, 2026 Brian Gastman: "Well, the majority of the patients now are on that lower dose. It is important to also note that that dose was actually available, excuse me, to patients well before we made that change in the protocol. The protocol, actually, all it did was it gave away the other option as well. But what we have seen is basically rock-steady response rates through multiple years and multiple data cuts that we have provided publicly, and we have seen long-term swimmers from this lower dose lymphodepletion." Noah Berkowitz CMO: "But I think more important, as importantly, the safety is improving, and so that is why we have made the change. It bodes well for the phase III eventually." Dan Kirby CCO: "Yeah, the short answer is no, we have not seen a difference of response or duration." My moneys on these guy's and not the scared money tools posting here.
2
1
24
863
$CAPR "It is very likely that the FDA will issue its decision on Friday, November 20, 2026—two days ahead of the November 22 target date. Because November 22, 2026 falls on a Sunday, standard FDA practice is to finalize and sign off on weekend PDUFA actions on the preceding business day." "Weekend Target Date. When a PDUFA goal date lands on a Saturday or Sunday, the FDA rarely issues decisions over the weekend. Instead, reviewers typically complete and digitally sign off on the action letter by Friday evening (November 20), with companies announcing the news after Friday's market close or before Monday's opening bell." GLA....
1
244
$BB Palo Alto Networks has signed a definitive agreement to acquire AI startup Applied Compute in an all-stock deal valued at $4.5 billion. Announced on November 18, 2026, the acquisition combines Palo Alto Networks' cybersecurity infrastructure with Applied Compute's open-weight AI platform. • Valuation and Structure. The transaction is an all-stock deal valued at $4.5 billion. • Expected Timeline. Subject to regulatory clearance and customary closing conditions, the deal is expected to close in Palo Alto Networks' fiscal third quarter of 2027. • Company Background. Founded by former OpenAI researchers (Yash Patil, Rhythm Garg, and Linden Li), Applied Compute grew from zero to over $100 million in annualized revenue run-rate in roughly 18 months.
1
134
$IBRX Still mindboggling p-value came in at 0.01 with full 370 patient count. Remaining stat data will be that much more stellar. And Adcock stating IBRX will be asking the FDA to approve Anktiva in ‘first-course’ BCG treatment. Now add the benefits of Anktiva increasing patients ALC count from day one. FDA cannot deny the benefits for patients will heal much quicker. “BCG-naïve patients respond relatively well to standard BCG alone—typically achieving around a 70% remission rate. Demonstrating a statistically significant improvement over an already active frontline standard in a 370-patient randomized trial is a higher bar to clear. * Progression from interim data. An earlier FDA-requested interim analysis on a smaller subset of patients showed a 9-month complete response durability of 84% for Anktiva plus BCG versus 52% for BCG alone, with a p-value of 0.0455. Reaching 0.01 in the full 370-patient final analysis shows the statistical signal strengthened as the sample size grew.
3
3
41
1,742
$CAPR The AdCom's word was "fragile." Here's what Capricor's robustness report, cited in the investigator letter, actually tested. Remove any single patient and rerun: the primary endpoint stays below p = 0.05 in 104 of 105 cases. Across 30 prespecified model specifications, the effect ranged 4.00 to 4.55 points. A randomization test over 20,000 reshuffles, with no model assumptions, gave p ≈ 0.03. Of 913 re-analyses, none favored placebo. A fragile result changes direction or size when you poke it. This one didn't.
1
13
1,212
$NIO Moat Update - 24-hour Swap, Nov 19, 2026, 08:00 China (CST) 108,600 Swaps Today, approximately 13.6% of all BaaS Cars. 105,475 Swaps Daily average on a trailing 28-day count. Total Swap 131,657,000. Up from 131,548,400 Yesterday. (BaaS Users ~ 60% of TTL 1,332,139 cars delivered end October) 4,269 Swap Stations, 1,084 on Highways. Plus 4 on Nov 18 Stations installed 2026 Q1=110 Q2=170 Q3=199 Q4=114 131 Million Swaps Milestone reached on Nov 13, 2026 Swap Progress: Stations TTL SWAP January 1. 2024 2,320 35,0 Million January 1. 2025 2,995 61,5 Million January 1. 2026 3,676 96,4 Million FULL Charge in approximately 3 minutes, remaining in the car. With Swap the battery is defect free, fresh and up to date. The first 10 million swaps took NIO four years. The fastest Million so far less than 6 days.
2
2
20
1,297